Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
2018-004091-35Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valproic acid and hydralazine in apudoma (NET), sponsored by Erasmus MC. Primary endpoint: SSTR2-related PET uptake response. Started Mar 2019; status: active.
02
Drugs
valproic acidhydralazine
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2018-004091-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004091-35.